Pulmonary Inflammation
5
0
0
1
Key Insights
Highlights
Success Rate
25% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
60.0%
3 terminated out of 5 trials
25.0%
-61.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic Fibrosis
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
Pulmonary and Systemic Effects of Exposure to Wood Smoke
Phase 1 Study Assessing the Safety and Tolerability of CTX-4430